{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"60.0","value":"22.2"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"41.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"12.7","upperLimit":"47.2","value":"27.6"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"45.4","value":"15.4"},{"groupId":"OG005","lowerLimit":"0.1","upperLimit":"22.8","value":"4.5"},{"groupId":"OG006","lowerLimit":"4.7","upperLimit":"50.8","value":"21.4"},{"groupId":"OG007","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"},{"groupId":"OG008","lowerLimit":"3.7","upperLimit":"71.0","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"description":"Complete response rate is defined as the percentage of participants achieving a complete response (CR) based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS as assessed by the investigator. CR for AML: - Absolute neutrophil count (ANC) \\> 1.0 x10⁹/L - Platelet count \\> 100 x10⁹/L - Bone marrow (BM) blasts \\< 5% - Absence of blasts with Auer rods - Independence of red cell transfusions CR for MDS: - Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines - Peripheral blood: -- Hemoglobin ≥ 11 g/dL -- Platelets ≥ 100 × 10⁹/L -- Neutrophils ≥ 1.0 × 10⁹/L -- Blasts = 0%","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 1 Dose Escalation: Enasidenib 50 mg"},{"description":"Participants who received a total daily dose of enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Phase 1 Dose Escalation: Enasidenib 60 mg"},{"description":"Participants who received a total daily dose of enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Phase 1 Dose Escalation: Enasidenib 75 mg"},{"description":"Participants who received a total daily dose of enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG003","title":"Phase 1 Dose Escalation: Enasidenib 100 mg"},{"description":"Participants who received a total daily dose of enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG004","title":"Phase 1 Dose Escalation: Enasidenib 150 mg"},{"description":"Participants who received a total daily dose of enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG005","title":"Phase 1 Dose Escalation: Enasidenib 200 mg"},{"description":"Participants who received a total daily dose of enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG006","title":"Phase 1 Dose Escalation: Enasidenib 300 mg"},{"description":"Participants who received a total daily dose of enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG007","title":"Phase 1 Dose Escalation: Enasidenib 450 mg"},{"description":"Participants who received a total daily dose of enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG008","title":"Phase 1 Dose Escalation: Enasidenib 650 mg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.","reportingStatus":"POSTED","timeFrame":"Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).","title":"Phase 1 Dose Escalation: Complete Response Rate (CRR) by Total Daily Dose","type":"SECONDARY","unitOfMeasure":"percentage of participants"}